Home > Products > Featured products
Cat. No. Product name CAS No.
DC20332 CD38 inhibitor 78c Featured

CD38 inhibitor 78c is a potent, specific, reversible CD38 inhibitor with Ki of 14.5 nM for recombinant human CD38.

1700637-55-3
DC10491 CD437 Featured

CD437 is a synthetic retinoid that is an RARγ-selective agonist. It displays RARγ-dependent and -independent effects on differentiation and apoptosis.

125316-60-1
DC10909 BN82002 Featured

CDC25 Phosphatase Inhibitor I, BN82002, is a cell-permeable ortho-hydroxybenzylamino compound that has been reported to display antitumor properties.

396073-89-5
DC8361 CDDO(Bardoxolone; RTA 401) Featured

CDDO is a synthetic oleanane triterpenoid that blocks the cellular synthesis of inducible nitric oxide synthase and inducible COX-2 in INF-γ-activated mouse macrophages with an IC50 value of 0.4 nM.

218600-44-3
DC12026 CDDO-2P-Imidazolide Featured

CDDO-2P-Im is a new analogue of CDDO-Imidazolid,showing better bioactive than CDDO-Imidazolid.

1883650-96-1
DC12027 CDDO-3P-Imidazolide Featured

CDDO-3P-Im is a new analogue of CDDO-Imidazolid,showing better bioactive than CDDO-Imidazolid.

1883650-95-0
DC12025 CDDO imidazolide Featured

CDDO-imidazolide is a potent inducer of heme oxygenase-1 and Nrf2/ARE signaling,with potent antiproliferative, differentiating, and anti-inflammatory activities.

443104-02-7
DC9277 C-DIM12 Featured

C-DIM12 is a novel synthetic activator of Nurr1.

178946-89-9
DC10792 DIM-C-pPhOCH3(C-DIM5) Featured

C-DIM5 is a Nur77 agonist. Activation of the orphan nuclear receptor Nur77 by C-DIM5 is associated with decreased cancer cell survival,

33985-68-1
DC20334 CDK2 inhibitor 73 Featured

CDK2 inhibitor 73 is a potent, selective CDK2 inhibitor with IC50 of 44 nM for CDK2/cyclin A, displays 2,000-fold selectivity over CDK1/cyclin B (IC50=86 uM)..

2079895-42-2
DC20335 CDK9-IN-8 Featured

CDK9-IN-8 is a highly potent, selective CDK9 inhibitor with IC50 of 12 nM, shows good selectivity in CDKs kinase profiling assay against CDK kinases and cell proliferation inhibition.

2105956-51-0
DC23138 CDK-I73 Featured

CDKI-73 is a potent CDK9 inhibitor with Ki of 4 nM, shows cytotoxicity against a broad CLL samples with mean LD50 of 80 nM.

1421693-22-2
DC9390 CDK-IN-2 Featured

CDK-IN-2 is a potent and sepecific CDK inhibitor.

1269815-17-9
DC11393 CDM-NAG Featured

CDM-NAG is a useful tool compound to deliver the siRNA.

1299292-01-5
DC10948 CDN1163 Featured

CDN1163 (CDN-1163) is a small molecule, allosteric activator of SERCA2, dose-dependently increases the Vmax of SERCA2 Ca2+-ATPase activity in ER microsomes; increases Ca2+-ATPase activity and significantly enhances Ca2+ uptake into the ER, attenuates H2O2-stimulated cell death in HEK cells; improves glucose homeostasis and metabolic parameters, increases glucose tolerance in ob/ob mice; CDN1163 reduces lipid accumulation and decreases lipogenesis in obese mice livers.

892711-75-0
DC23463 CDPPB Featured

CDPPB is a potent, selective, brain penetrant positive allosteric modulator of mGlu5 receptor with EC50 of 10 nM and 20 nM for human and rat mGluR5, respectively.

781652-57-1
DC20336 CE3F4 Featured

CE3F4 is a potent, noncompetitive EPAC1 inhibitor that blocks EPAC1-induced Rap1 activation both in cell-free systems and in intact cells and did not influence protein kinase A holoenzyme activity.

143703-25-7
DC20987 Cedazuridine Featured

Cedazuridine (E7727) is a novel cytidine deaminase inhibitor, and a componet of ASTX727 for treatment of hematologic malignancies..

1141397-80-9
DC3170 Cediranib Featured

Cediranib (AZD2171) is a highly potent VEGFR2 inhibitor with IC50 of 0.5 nM, also inhibits Flt1/4 with IC50 of 5 nM/≤3 nM.

288383-20-0
DC8067 Cefozopran Featured

Cefozopran (SCE-2787) is a new parenteral cephalosporin, against experimental infections in mice.

113359-04-9
DCAPI1155 Celastrol Featured

Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

34157-83-0
DCAPI1491 Celecoxib Featured

Celecoxib is a selective Cox-2 inhibitor (IC50 of 40 nM). Celecoxib shows low sensitivity against Cox-1 (IC50 of 15 μM). Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 (IC50of 32.86 μM) and CNE1-LM

169590-42-5
Page 60 / Total 440 FirstPrevNextLastGoto